153 related articles for article (PubMed ID: 23163132)
1. Erratum to "IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer" [Clin. Lab. 2012; 58:501-505].
Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
Clin Lab; 2012; 58(9-10):1103-7. PubMed ID: 23163132
[TBL] [Abstract][Full Text] [Related]
2. IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.
Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
Clin Lab; 2012; 58(5-6):501-5. PubMed ID: 22783581
[TBL] [Abstract][Full Text] [Related]
3. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.
Bisgin A; Kargi A; Yalcin AD; Aydin C; Ekinci D; Savas B; Sanlioglu S
BMC Cancer; 2012 Feb; 12():58. PubMed ID: 22313795
[TBL] [Abstract][Full Text] [Related]
4. Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.
Celik B; Yalcin AD; Bisgin A; Dimitrakopoulou-Strauss A; Kargi A; Strauss LG
Med Sci Monit; 2013 Oct; 19():875-82. PubMed ID: 24145180
[TBL] [Abstract][Full Text] [Related]
5. Blood eosinophil and platelet levels, proteomics patterns of trail and CXCL8 correlated with survival in bevacizumab treated metastatic colon cancers.
Yalcin AD; Kargi A; Gumuslu S
Clin Lab; 2014; 60(2):339-40. PubMed ID: 24660552
[TBL] [Abstract][Full Text] [Related]
6. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
7. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
8. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
10. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
12. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
Akman A; Yilmaz E; Mutlu H; Ozdogan M
Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
14. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
16. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
20. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D; Claes B; Delmar P; Reumers J; Mazzone M; Yesilyurt BT; Devlieger R; Verslype C; Tejpar S; Wildiers H; de Haas S; Carmeliet P; Scherer SJ; Van Cutsem E
Lancet Oncol; 2012 Jul; 13(7):724-33. PubMed ID: 22608783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]